Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
The Journal of Antimicrobial Chemotherapy|September 23, 2016
Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patientsSergio Serrano-Villar, Yan Zhou, Anthony J Rodgers, et al.Pharmaceutical Statistics|August 8, 2023
Calculation of Phase 2 dose-finding study sample size for reliable Phase 3 dose selectionFang Liu, Qing Zhao, Anthony J Rodgers, et al.Current Medical Research and Opinion|January 9, 2007
The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic painJacques E Chelly, Carl W Nissen, Anthony J Rodgers, et al.Headache|November 3, 2010
Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study databaseAnthony J Rodgers, Carolyn M Hustad, Roger K Cady, et al.Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.Alimentary Pharmacology & Therapeutics|February 21, 2025
Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASHAnnaswamy Raji, Ira Gantz, Michael Crutchlow, et al.The Lancet. HIV|December 12, 2018
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trialSharon Nachman, Carmelita Alvero, Hedy Teppler, et al.Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2013
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJürgen K Rockstroh, Edwin DeJesus, Jeffrey L Lennox, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.Pageof 2